Pharmaceutical Composition for Bone Loss Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Postmenopausal osteoporosis, characterized by significant bone loss due to estrogen deficiency, is challenging to treat effectively without causing serious side effects from long-term hormone therapy, and existing treatments fail to adequately address bone mineral density, bone mineral content, and alkaline phosphatase activity.

Innovation Solution

A pharmaceutical composition comprising licorice, black bean, Cnidi Fructus, buckhorn, imperatorin, and bergapten, administered in specific weight ratios, is used to prevent, ameliorate, or treat bone loss, increasing bone mineral density, bone mineral content, and alkaline phosphatase activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If hormone treatment is used to suppress postmenopausal osteoporosis, then bone loss is reduced, but serious side effects occur with long-term use

Engineering Contradiction:

Improveeffectiveness in suppressing bone lossVSAvoidside effects from long-term hormone therapy

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the beneficial effect of estrogen on bone protection while eliminating the harmful side effects by using imperatorin and bergapten as alternative active ingredients that can suppress bone loss without causing the serious side effects associated with long-term hormone therapy

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the chemical parameter from natural estrogen to imperatorin and bergapten, which have similar bone-protective effects but different safety profiles, thereby resolving the contradiction between effectiveness and side effects

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing treatments are used for osteoporosis, then some bone protection is achieved, but they fail to adequately address bone mineral density, bone mineral content, and alkaline phosphatase activity

Engineering Contradiction:

Improvebone protection effectVSAvoidadequacy in addressing bone mineral density, content, and ALP activity

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent creates a multi-functional pharmaceutical composition that simultaneously addresses multiple bone health parameters including bone mineral density, bone mineral content, and alkaline phosphatase activity, rather than focusing on a single parameter

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Stability of the object's composition

If estrogen is absent, then bone loss occurs and calcium ion balance is disrupted, but hormone therapy causes serious side effects

Engineering Contradiction:

Improvecalcium ion balance and bone compositionVSAvoidside effects from hormone replacement

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent uses imperatorin and bergapten as intermediary substances that can mediate the bone-protective effects normally provided by estrogen, thereby maintaining calcium ion balance and bone composition stability without requiring actual hormone replacement

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS7914821B2Pharmaceutical composition for prevention and/or treatment of bone loss

Publication Date: 2011.03.29 KO PHARML

AI summary

A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn.